Abstract: Methods of treating a nerve injury are disclosed. The methods include administering to a target site of the nerve injury a thermally stable preparation having a purified amphiphilic peptide in an aqueous biocompatible solution, being configured to self-assemble into a hydrogel, and administering to the target site a buffer having an effective amount of an ionic salt and a biological buffering agent to form the hydrogel. The methods include administering to the target site a biological material suspension in an amount effective to treat the nerve injury. The methods include administering to the target site an anti-scarring agent in an amount effective to treat the nerve injury. The target site is associated with central nervous system tissue or peripheral nervous system tissue. The nerve injury includes spinal cord injury and peripheral nerve injury.

Abstract: Preparations capable of forming films are disclosed. The preparations include a biocompatible polymer and a purified amphiphilic peptide including a folding group having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern and a turn sequence, and at least one functional group available for crosslinking. The purified amphiphilic peptide is crosslinked with the biocompatible polymer to form the film. Kits for producing the film are also disclosed. Methods of producing the film are also disclosed.

Abstract: Preparations including a purified amphiphilic peptide including a folding group having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern and a turn sequence, configured to self-assemble into a hydrogel and being thermally stable are disclosed. The peptide may have a net charge of from ?7 to +11. The peptide may include an effective amount of counterions. The preparation may include between 0.5% w/v and 6.0% w/v of the peptide. The preparation may include a biocompatible solution. The preparation may include a buffer. The buffer may include an effective amount of an ionic salt and a biological buffering agent to form the hydrogel. Kits including the preparation are also disclosed. The kits may include a mixing device and/or a delivery device. Medical or surgical tools having at least a portion of an exterior surface coated with the hydrogel are also disclosed.

Abstract: Methods of treating a microbial contamination are disclosed. Methods of eliminating or inhibiting proliferation of a target microorganism at a target site are also disclosed. The methods include administering a thermally stable preparation comprising a purified amphiphilic peptide in an aqueous biocompatible solution and administering a buffer to a target site. The peptide has a folding group having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern and a turn sequence. The peptide is configured to self-assemble into a hydrogel.

Abstract: Methods of treating a fungal contamination are disclosed. Methods of eliminating or inhibiting proliferation of a target fungal organism at a target site are also disclosed. The methods include administering a thermally stable preparation comprising a purified amphiphilic peptide in a biocompatible solution and administering a buffer to a target site. The peptide has a folding group having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern and a turn sequence. The peptide is configured to self-assemble into a hydrogel.

Abstract: Materials and methods for forming a bronchial obstruction are provided. A peptide comprising between about 7 amino acids and about 32 amino acids in a solution may be introduced to a target site. A hydrogel barrier may be provided at the target site in order to provide a bronchial obstruction.

Abstract: The present disclosure provides peptide compositions (e.g., of self-assembling peptides) with particular attributes (e.g., peptide identity, peptide concentration, pH, ionic strength [including salt identity and/or concentration), etc that show particularly useful material properties. The present disclosure also provides technologies for selecting and/or formulating particular peptide compositions useful in specific contexts. In some embodiments, provided peptide compositions have an elevated pH within the range of about 2.5 to about 3.5 and/or an ionic strength that is above that of a corresponding composition of the same peptide, at the same concentration, in water, but is below a critical salt point for the peptide (e.g., so that the composition is not cloudy).

Abstract: A biological fluid sample analysis chamber and a method for analyzing a biological fluid sample is provided. The chamber includes a first chamber panel, a second chamber panel, and a plurality of beads disposed between the first chamber panel and the second chamber panel, which beads are configured to not reflect light incident to the beads in an amount that appreciably interferes with a photometric analysis of the biologic fluid.

Abstract: The present disclosure provides peptide compositions (e.g., of self-assembling peptides) with particular attributes (e.g., peptide identity, peptide concentration, pH, ionic strength [including salt identity and/or concentration), etc that show particularly useful material properties. The present disclosure also provides technologies for selecting and/or formulating particular peptide compositions useful in specific contexts. In some embodiments, provided peptide compositions have an elevated pH within the range of about 2.5 to about 3.5 and/or an ionic strength that is above that of a corresponding composition of the same peptide, at the same concentration, in water, but is below a critical salt point for the peptide (e.g., so that the composition is not cloudy).

Abstract: The present disclosure provides peptide compositions (e.g., of self-assembling peptides) with particular attributes (e.g., peptide identity, peptide concentration, pH, ionic strength [including salt identity and/or concentration), etc. that show particularly useful material properties. The present disclosure also provides technologies for selecting and/or formulating particular peptide compositions useful in specific contexts. In some embodiments, provided peptide compositions have an elevated pH within the range of about 2.5 to about 3.5 and/or an ionic strength that is above that of a corresponding composition of the same peptide, at the same concentration, in water, but is below a critical salt point for the peptide (e.g., so that the composition is not cloudy).

Abstract: Materials and methods for treatment of pulmonary bulla are provided. A peptide comprising between about 7 amino acids and about 32 amino acids in a solution may be introduced to a target site. A hydrogel barrier may be provided at the target site in order to treat the pulmonary bulla.

Abstract: Materials and methods for forming a bronchial obstruction are provided. A peptide comprising between about 7 amino acids and about 32 amino acids in a solution may be introduced to a target site. A hydrogel barrier may be provided at the target site in order to provide a bronchial obstruction.

Abstract: Materials and methods for treatment of pulmonary leakage are provided. A peptide comprising between about 7 amino acids and about 32 amino acids in a solution may be introduced to a target site. A hydrogel barrier may be provided at the target site in order to treat the pulmonary leakage.

Abstract: Materials and methods for treatment of pulmonary bulla are provided. A peptide comprising between about 7 amino acids and about 32 amino acids in a solution may be introduced to a target site. A hydrogel barrier may be provided at the target site in order to treat the pulmonary bulla.

Abstract: The present disclosure provides peptide compositions (e.g., of self-assembling peptides) with particular attributes (e.g., peptide identity, peptide concentration, pH, ionic strength [including salt identity and/or concentration), etc that show particularly useful material properties. The present disclosure also provides technologies for selecting and/or formulating particular peptide compositions useful in specific contexts. In some embodiments, provided peptide compositions have an elevated pH within the range of about 2.5 to about 3.5 and/or an ionic strength that is above that of a corresponding composition of the same peptide, at the same concentration, in water, but is below a critical salt point for the peptide (e.g., so that the composition is not cloudy).

Abstract: A biological fluid sample analysis chamber and a method for analyzing a biological fluid sample is provided. The chamber includes a first chamber panel, a second chamber panel, and a plurality of beads disposed between the first chamber panel and the second chamber panel, which beads are configured to not reflect light incident to the beads in an amount that appreciably interferes with a photometric analysis of the biologic fluid.

Abstract: Well plates for use in various laboratory experiments may include a plurality of wells each having an interior wall that includes a ledge positioned at a fixed depth within the well.

Abstract: A device for volumetric metering a liquid biologic sample is provided. The device includes an initial chamber, a second chamber, a third chamber, a first valve, a second valve and a third valve. The chambers are each configured so that liquid sample disposed in the respective chamber is subject to capillary forces. Each chamber has a volume, and the volume of the initial chamber is greater than the volume of either the second or the third chambers. The valves each have a burst pressure. The burst pressure of the first valve is greater than the third burst pressure. The first valve is in fluid communication with the second chamber. The second valve is disposed between, and is in fluid communication with, the initial chamber and the third chamber. The third valve is in fluid communication with the third chamber.